Form 4: Vor Biopharma Director Erez Kalir Acquires Stock Options

Vor Biopharma director Erez Kalir was granted stock options for 60,000 shares at an exercise price of $1.74.

Summary

• Erez Kalir, a director at Vor Biopharma, was granted stock options to purchase 60,000 shares of common stock.
• The exercise price for these options is $1.74 per share.
• The options vest monthly over three years, starting February 6, 2025, contingent on continued service.
• The options expire on January 5, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The director's stock options will vest over the next three years, subject to continued service.

Management Comments

• Mr. Kalir was elected to the board of directors of the Issuer as a designee of Reprogrammed Interchange LLC.

Industry Context

Stock option grants are a common practice for incentivizing directors and aligning their interests with the company's performance in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry, often with vesting schedules tied to continued service.
• The exercise price of $1.74 is specific to Vor Biopharma's stock and market conditions at the time of the grant.
• Vesting periods of three years are common, aligning with typical long-term incentive plans.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, director, Vor Biopharma, equity